Send to

Choose Destination
J Radiat Oncol. 2013 Mar;2(1):63-70. Epub 2012 Sep 12.

Stereotactic body radiation therapy for the primary treatment of localized prostate cancer.

Author information

Drexel University College of Medicine/Hahnemann University Hospital, 230 N Broad St, Philadelphia, PA 19102 USA ; Philadelphia CyberKnife Center, 2010 West Chest Pike Suite 115, Havertown, PA 19083 USA.



The low alpha/beta ratio of prostate cancer suggests that hypofractionated schemes of dose-escalated radiotherapy should be advantageous. We report our experience using stereotactic body radiation therapy (SBRT) for the primary treatment of prostate cancer to assess efficacy and toxicity.


From 2007 to 2010, 70 patients (51 % low risk, 31 % intermediate risk, and 17 % high risk) with localized prostate cancer were treated with SBRT using the CyberKnife system. One-third of patients received androgen deprivation therapy. Doses of 37.5 Gy (n = 29), 36.25 Gy (n = 36), and 35 Gy (n = 5) were administered in five fractions and analyzed as high dose (37.5 Gy) vs. low dose (36.25 and 35 Gy).


At a median 27 and 37 months follow-up, the low and high dose groups' median PSA nadir to date was 0.3 and 0.2 ng/ml, respectively. The 3-year freedom from biochemical failure (FFBF) was 100 %, 95.0 % and 77.1 % for the low-, intermediate- and high-risk patients. A dose response was observed in intermediate- and high-risk patients with 72 % vs. 100 % 3-year FFBF for the low and high dose groups, respectively (p = 0.0363). Grade III genitourinary toxicities included 4 % acute and 3 % late (all high dose). Potency was preserved in 83 % of hormone naïve patients.


CyberKnife dose escalated SBRT for low-, intermediate- and high-risk prostate cancer exhibits favorable efficacy with acceptable toxicity.


Alpha/beta ratio; Dose escalation; Hypofractionation; Prostate cancer; Stereotactic body radiation therapy

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center